Equities researchers at StockNews.com began coverage on shares of Pulmatrix (NASDAQ:PULM – Get Free Report) in a research note issued on Tuesday. The brokerage set a “hold” rating on the biotechnology company’s stock.
Pulmatrix Price Performance
PULM opened at $2.09 on Tuesday. The stock has a market capitalization of $7.63 million, a price-to-earnings ratio of -0.54 and a beta of 0.92. The business has a 50-day moving average of $1.82 and a two-hundred day moving average of $1.88. Pulmatrix has a 12 month low of $1.55 and a 12 month high of $3.14.
Pulmatrix (NASDAQ:PULM – Get Free Report) last posted its quarterly earnings results on Thursday, March 28th. The biotechnology company reported ($0.57) EPS for the quarter. The business had revenue of $2.20 million during the quarter. Pulmatrix had a negative net margin of 193.49% and a negative return on equity of 63.94%.
Hedge Funds Weigh In On Pulmatrix
About Pulmatrix
Pulmatrix, Inc, a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Featured Articles
- Five stocks we like better than Pulmatrix
- Stock Sentiment Analysis: How it Works
- The Charles Schwab Company Can Hit New Highs
- What is the FTSE 100 index?
- Costco vs. Walmart: Revenue Comparison of Two Retail Giants
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- 3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.